Copyright
©The Author(s) 2017.
World J Stem Cells. Aug 26, 2017; 9(8): 133-143
Published online Aug 26, 2017. doi: 10.4252/wjsc.v9.i8.133
Published online Aug 26, 2017. doi: 10.4252/wjsc.v9.i8.133
Table 4 Scores of extended Glasgow Outcome Scale of the treatment group (n = 5) having mesenchymal stem cell therapy at the 1st, 12th, 16th, 24th, 36th and 60th week upon completion of the study
| Study duration (wk) | Scores of extended glasgow outcome scale | P value | ||||
| UPN02 | UPN08 | UPN09 | UPN10 | UPN11 | ||
| 1st | 3 | 4 | 3 | 3 | 4 | |
| 12th | 3 | 4 | 3 | 3 | 4 | 1 |
| 16th | 3 | 4 | 3 | 3 | 4 | 1 |
| 24th | 3 | 4 | 3 | 3 | 5 | 0.19 |
| 36th | 3 | 5 | 3 | 3 | 5 | 0.09 |
| 60th | 4 | 6 | 3 | - | 5 | 0.05 |
- Citation: Tsang KS, Ng CPS, Zhu XL, Wong GKC, Lu G, Ahuja AT, Wong KSL, Ng HK, Poon WS. Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal stem cell therapy for chronic stroke. World J Stem Cells 2017; 9(8): 133-143
- URL: https://www.wjgnet.com/1948-0210/full/v9/i8/133.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v9.i8.133